Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Diagnostics

Background:

• Prostate cancer (PCa) diagnosis relies on invasive methods.
• Noninvasive epigenetic biomarkers from blood are needed for early PCa detection.
• Tumor suppressor genes like RASSF1A, MGMT, PTEN, and SOCS3 are implicated in cancer development.

Purpose of the Study:

• To assess promoter methylation of RASSF1A, MGMT, PTEN, and SOCS3 in PCa patients versus controls.
• To evaluate the diagnostic utility of these genes as blood-based epigenetic biomarkers for PCa.
• To correlate methylation status with PCa stage.

Main Methods:

• Pyrosequencing analysis of promoter methylation in four key tumor suppressor genes.
• Comparison of methylation levels between 41 PCa patients and 10 healthy controls.
• Correlation of methylation patterns with localized versus locally advanced PCa.

Main Results:

• No significant difference in RASSF1A, MGMT, or PTEN promoter methylation between PCa patients and controls.
• Elevated SOCS3 promoter methylation observed in patients with locally advanced PCa compared to localized PCa.
• No significant difference in methylation for RASSF1A, MGMT, and PTEN between localized and locally advanced PCa.

Conclusions:

• SOCS3 promoter methylation shows potential as a noninvasive biomarker for detecting locally advanced PCa.
• RASSF1A, MGMT, and PTEN methylation levels in blood do not appear useful for PCa diagnosis in this cohort.
• Further validation of SOCS3 as a biomarker for advanced PCa is warranted.